Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, aXichem AB's enterprise value is kr139.97 Mil.
aXichem AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr-10.26 Mil. Therefore, aXichem AB's EV-to-EBITDA for today is -13.65.
The historical rank and industry rank for aXichem AB's EV-to-EBITDA or its related term are showing as below:
OSTO:AXIC A'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -165.72 Med: -19.11 Max: -2.23
Current: -13.65
During the past 13 years, the highest EV-to-EBITDA of aXichem AB was -2.23. The lowest was -165.72. And the median was -19.11.
OSTO:AXIC A's EV-to-EBITDA is ranked worse than 100% of 1342
companies
in the Chemicals industry
Industry Median: 12.36
vs OSTO:AXIC A: -13.65
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
aXichem AB's share price for today is kr2.10.
aXichem AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.249.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for aXichem AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:AXIC A vs LIN, SHW, ECL: EV-to-EBITDA Comparison
For the Specialty Chemicals subindustry, aXichem AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aXichem AB EV-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, aXichem AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where aXichem AB's EV-to-EBITDA falls into.
aXichem AB's current Enterprise Value is kr139.97 Mil.
aXichem AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-10.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aXichem AB (OSTO:AXIC A) has a EV-to-EBITDA of -13.65 as of Sep. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on aXichem AB. According to the industry distribution chart, aXichem AB ranks #999999 out of 1342 companies in the Chemicals industry.
Is aXichem AB's EV-to-EBITDA too high?
aXichem AB's current EV-to-EBITDA is -13.65. Based on the distribution chart, aXichem AB ranks #999999 out of 1342 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, aXichem AB has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does aXichem AB's EV-to-EBITDA compare to LIN and SHW?
According to the Chemicals industry distribution chart, aXichem AB ranks #999999 out of 1342 companies for EV-to-EBITDA. This places aXichem AB in the lower half of its industry. The industry median EV-to-EBITDA is 12.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Chemicals company?
The median EV-to-EBITDA among Chemicals companies is 12.36, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on aXichem AB. For the Chemicals industry, the median EV-to-EBITDA is 12.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aXichem AB's current EV-to-EBITDA is -13.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aXichem AB stock overvalued right now?
Based on GuruFocus' analysis, aXichem AB (OSTO:AXIC A) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2.51, compared to a current price of kr2.10 — trading 16.3% below its estimated fair value. The current EV-to-EBITDA is -13.65. aXichem AB's overall GF Score™ is 61/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For aXichem AB (OSTO:AXIC A), the current EV-to-EBITDA is -13.65 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aXichem AB (OSTO:AXIC A) Overvalued in 2026?
Based on GuruFocus' analysis, aXichem AB stock appears to be undervalued.
The current stock price of kr2.10 is trading 16.3% below its estimated GF Value™ of kr2.51.
GuruFocus considers aXichem AB to be Modestly Undervalued.
Key valuation signals for OSTO:AXIC A:
EV-to-EBITDA: -13.65
GF Value™: kr2.51 vs. price of kr2.10 (16.3% below fair value)
No single metric tells the full story. See the OSTO:AXIC A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aXichem AB develops, patents, markets and sells natural analogue industrial chemicals, which are synthetically produced substances with similar and comparable properties to natural substances. The Company's business concept is to develop, patent, market and sell natural analogue industrial chemicals. Its commercial focus is on the proprietary patented product phenylcapsaicin, the Company's first product, which is marketed under the registered trademarks aXiphen as an additive in animal feed and aXivite as an ingredient in food supplements and as a bioenhancer. The Company's product portfolio comprises Phenylcapsaicin, aXiphen, aXiphen bio, and aXivite. The Company's focus is on establishing aXiphen as an additive in poultry feed and pig feed.
61GF Score
Get the complete analysis for OSTO:AXIC A
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:AXIC A has been successfully added to your 
